Abstract:Background: Evidence-based treatment decisions in medicine are made founded on population-level evidence obtained during randomized clinical trials. In an era of personalized medicine, these decisions should be based on the predicted benefit of a treatment on a patient-level. Survival prediction models play a central role as they incorporate the time-to-event and censoring. In medical applications uncertainty is critical especially when treatments differ in their side effect profiles or costs. Additionally, models must be adapted to local populations without diminishing performance and often without the original training data available due to privacy concern. Both points are supported by Bayesian models-yet they are rarely used. The aim of this work is to evaluate Bayesian parametric survival models on public datasets including cardiology, infectious diseases, and oncology. Materials and methods: Bayesian parametric survival models based on the Exponential and Weibull distribution were implemented as a Python package. A linear combination and a neural network were used for predicting the parameters of the distributions. A superiority design was used to assess whether Bayesian models are better than commonly used models such as Cox Proportional Hazards, Random Survival Forest, and Neural Network-based Cox Proportional Hazards. In a secondary analysis, overfitting was compared between these models. An equivalence design was used to assess whether the prediction performance of Bayesian models after model updating using Bayes rule is equivalent to retraining on the full dataset. Results: In this study, we found that Bayesian parametric survival models perform as good as state-of-the art models while requiring less hyperparameters to be tuned and providing a measure of the uncertainty of the predictions. In addition, these models were less prone to overfitting. Furthermore, we show that updating these models using Bayes rule yields equivalent performance compared to models trained on combined original and new datasets. Conclusions: Bayesian parametric survival models are non-inferior to conventional survival models while requiring less hyperparameter tuning, being less prone to overfitting, and allowing model updating using Bayes rule. Further, the Bayesian models provide a measure of the uncertainty on the statistical inference, and, in particular, on the prediction.

Prediction of cancer dynamics under treatment using Bayesian neural networks: A simulated study

Nonlinear Multilevel Joint Model for Individual Lesion Kinetics and Survival to Characterize Intra-Individual Heterogeneity in Patients with Advanced Cancer

Improving personalized tumor growth predictions using a Bayesian combination of mechanistic modeling and machine learning

Data Requirements for Model-Based Cancer Prognosis Prediction

Towards personalized computer simulations of breast cancer treatment

Predicting Radiotherapy Patient Outcomes with Real-Time Clinical Data Using Mathematical Modelling

A Bayesian joint model of multiple nonlinear longitudinal and competing risks outcomes for dynamic prediction in multiple myeloma: joint estimation and corrected two-stage approaches

Hybridizing mechanistic mathematical modeling with deep learning methods to predict individual cancer patient survival after immune checkpoint inhibitor therapy

Bayesian parametric models for survival prediction in medical applications

A Bayesian hierarchical model for prediction of latent health states from multiple data sources with application to active surveillance of prostate cancer

Predicting the Progression of Cancerous Tumors in Mice: A Machine and Deep Learning Intuition

Training with Small Medical Data: Robust Bayesian Neural Networks for Colon Cancer Overall Survival Prediction

Computational prediction of therapeutic response and cancer outcomes

Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth

Machine learning and mechanistic modeling for prediction of metastatic relapse in early-stage breast cancer

Prediction of Treatment Recommendations Via Ensemble Machine Learning Algorithms for Non-Small Cell Lung Cancer Patients in Personalized Medicine

Raman spectroscopy and artificial intelligence to predict the Bayesian probability of breast cancer

Personalized Risk Prediction for Cancer Survivors: A Bayesian Semi-parametric Recurrent Event Model with Competing Outcomes

Combined Stochastic Models for the Evaluation of Cancer Progression and Patient Trajectories

Deep Learning-based Prediction of Breast Cancer Tumor and Immune Phenotypes from Histopathology